Official Congress Report

XXIII International Bile Acid Meeting: Bile Acids as Signal Integrators and Metabolic Modulators

Falk Symposium 194
Freiburg, October 8–9, 2014

Editors
D. Häussinger, Düsseldorf
U. Beuers, Amsterdam
V. Keitel, Düsseldorf
M. Trauner, Vienna

40 figures and 8 tables, 2015
Disclaimer
The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'General Information').

© Copyright 2015 by S. Karger AG,
P.O. Box, CH–4009 Basel (Switzerland)
Printed on acid-free and non-aging paper (ISO 9706)
ISBN 978–3–318–05434–7
e-ISBN 978–3–318–05435–4
Contents

299 Preface
Häussinger, D. (Düsseldorf)

Bile Acids as Signal Integrators

300 Progesterone Metabolites as Farnesoid X Receptor Inhibitors
Abu-Hayyeh, S.; Williamson, C. (London)

307 Diet1 Is a Regulator of Fibroblast Growth Factor 15/19-Dependent Bile Acid Synthesis
Reue, K.; Lee, J.M.; Vergnes, L. (Los Angeles, Calif.)

314 ATP8B1 and ATP11C: Two Lipid Flippases Important for Hepatocyte Function
Naik, J.; de Waart, D.R.; Utsunomiya, K.; Duijst, S.; Mok, K.H.; Oude Elferink, R.P.J.; Bosma, P.J.; Paulusma, C.C. (Amsterdam)

Bile Acids and Liver Regeneration

319 The Bile Acid Receptor TGR5 and Liver Regeneration
Jourdainne, V.; Péan, N.; Doignon, I. (Orsay); Humbert, L.; Rainteau, D. (Paris); Tordjmann, T. (Orsay)

327 Bile Acids as Hormones: The FXR-FGF15/19 Pathway
Kliewer, S.A.; Mangelsdorf, D.J. (Dallas, Tex.)

332 Bile Acids and Stellate Cells
Kordes, C.; Sawitza, I.; Götz, S.; Häussinger, D. (Düsseldorf)

Interaction of Bile Acids and the Gut Microbiome

338 Gut Microbiota, Cirrhosis, and Alcohol Regulate Bile Acid Metabolism in the Gut
Ridlon, J.M.; Kang, D.-J.; Hylemon, P.B.; Bajaj, J.S. (Richmond, Va.)

346 Relationship between Obesity, Gut Microbiome and Hepatocellular Carcinoma Development
Hara, E. (Tokyo)

351 Interactions between Diet, Bile Acid Metabolism, Gut Microbiota, and Inflammatory Bowel Diseases
Devkota, S. (Boston, Mass.); Chang, E.B. (Chicago, Ill.)

357 Nuclear Receptors in Acute and Chronic Cholestasis
Gonzalez-Sanchez, E.; Firrincieli, D.; Housset, C.; Chignard, N. (Paris)
Bile Acids as Metabolic Modulators

367 Bile Acid-Induced Cholemic Nephropathy
  Krones, E.; Wagner, M.; Eller, K.; Rosenkranz, A.R. (Graz); Trauner, M. (Vienna);
  Fickert, P. (Graz)

376 Stimulation of Apical Sodium-Dependent Bile Acid Transporter Expands the Bile Acid Pool and Generates Bile Acids with Positive Feedback Properties
  Rudling, M.; Bonde, Y. (Stockholm)

382 Impact of Inhibiting Ileal Apical versus Basolateral Bile Acid Transport on Cholesterol Metabolism and Atherosclerosis in Mice
  Dawson, P.A. (Atlanta, Ga.)

Clinical Relevance of Bile Acid Metabolism and Transport

388 Sodium Taurocholate Cotransporting Polypeptide Acts as a Receptor for Hepatitis B and D Virus
  Yan, H.; Li, W. (Beijing)

397 The Cholangiocyte Glycocalyx Stabilizes the ‘Biliary HCO₃⁻ Umbrella’: An Integrated Line of Defense against Toxic Bile Acids
  Maillette de Buy Wenniger, L.J. (Amsterdam); Hohenester, S. (Amsterdam/Munich);
  Maroni, L. (Amsterdam/Ancona); van Vliet, S.J.; Oude Elferink, R.P.; Beuers, U.
  (Amsterdam)

408 Genetic Contributors and Modifiers of Biliary Atresia
  Mezina, A.; Karpen, S.J. (Atlanta, Ga.)

415 Nuclear Receptor Variants in Liver Disease
  Zimmer, V.; Liebe, R.; Lammert, F. (Homburg)

420 TGR5 in the Cholangiociliopathies
  Masyuk, T.V.; Masyuk, A.I.; La Russo, N.F. (Rochester, Minn.)

Therapeutic Potential of Bile Acids and Bile Acid Receptor Agonsists

426 Use of Farnesoid X Receptor Agonsists to Treat Nonalcoholic Fatty Liver Disease
  Sanyal, A.J. (Richmond, Va.)

433 Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders
  Trauner, M.; Halilbasic, E.; Claudel, T.; Steinacher, D.; Fuchs, C. (Vienna);
  Moustafa, T.; Pollheimer, M.; Krones, E. (Graz); Kienbacher, C.; Traussnigg, S.;
  Kazemi-Shirazi, L.; Munda, P.; Hofer, H. (Vienna); Fickert, P. (Graz);
  Paumgartner, G. (Vienna)

440 Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
  Kohli, R. (Cincinnati, Ohio); Myronovych, A. (Cincinnati, Ohio/Ann Arbor, Mich.);
  Tan, B.K.; Salazar-Gonzalez, R.-M.; Miles, L.; Zhang, W.; Oehrle, M. (Cincinnati, Ohio);
  Sandoval, D.A. (Ann Arbor, Mich.); Ryan, K.K. (Davis, Calif.);
  Seeley, R.J. (Ann Arbor, Mich.); Setchell, K.D.R. (Cincinnati, Ohio)

447 Falk Symposium Series

450 Author Index

451 Subject Index